THE CURE

India Today - - 50 POWER PEOPLE -

Be­cause de­spite the chal­lenges posed by the US Food and Drug Ad­min­is­tra­tion warn­ing let­ters, Sun Pharma posted a 10 per cent growth in 2018-19 rev­enues

Be­cause his Sun Pharma launched Ilumya in the US, be­com­ing the first In­dian pharma com­pany to launch a di­rect-to-cus­tomer cam­paign in the US

Be­cause he is still on the prowl to ac­quire com­pa­nies that are strate­gic fits, Pola Pharma Inc., a Ja­panese phar­ma­ceu­ti­cal com­pany be­ing one of the lat­est

LINE OF CAU­TION

Whis­tle blow­ers’ let­ters al­leg­ing cor­po­rate gov­er­nance lapses in the com­pany re­gard­ing re­lated party deals, caused its shares to tum­ble 13 per cent—a six-year low—on Jan­uary 18 this year on the stock ex­changes

KAN­ISHKA SONTHALIA/GETTY IMAGES

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.